Improving Total Cost of Care for Patients with Diabetes and Cardiovascular Disease
Tuesday, December 10 | 1:30 pm Eastern
Diabetes impacts about 1 in 10 Americans, 90 to 95% of whom have type 2 diabetes. Among adults with type 2 diabetes, 1 in 5 also has cardiovascular disease. Diabetes and cardiovascular disease independently account for significant clinical and financial costs, but taken together, the costs multiply. In fact, according to the National Diabetes Association, 52% of U.S. healthcare spend in 2012 was attributed to complications of diabetes due to cardiovascular disease.
Employers bear a significant portion of these costs.The direct cost of type 2 diabetes with at least one diabetes-related complication was $38,849 per patient per year in 2012. These costs continue to rise.
Can medication choices reduce overall costs?
During this live webinar, Dr. Sharon Frazee, PBMI's Senior Vice President of Research and Data Innovation, will take a deep dive into costs associated with diabetes and new PBMI analysis showing the impact of one class of medications on improving total cost of care. Dr. Frazee will illustrate:
- The cost implications for employers from type 2 diabetes and cardiovascular disease
- Current guidelines for treatment
- Results of current research demonstrating cost savings
We will have a Q&A session at the end of the webinar so you can get your top questions answered.
Sharon Glave Frazee, PhD, MPH
Senior Vice President of Research and Data Innovation, PBMI